Stockscreener 앱 받기
19.75
3.94%
-0.81
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Canada
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal
Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks
Aktis Oncology director Foley buys $4.19 million in shares - Investing.com
Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria
Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com India
Hedge Fund and Insider Trading News: Crispin Odey, Bill Ackman, Warren Buffett, Ray Dalio, ExodusPoint Capital, Saba Capital Management, Aktis Oncology Inc (AKTS), Warrior Met Coal Inc (HCC), and More - Insider Monkey
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Investing.com
A Fresh IPO That Long-Term Investors Shouldn't Ignore - Finviz
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Yahoo Finance
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Movement And Ongoing Losses - simplywall.st
Insider Stock Purchases: January 13, 2026 - Quiver Quantitative
Aktis Oncology Stock (AKTS) Opinions on Upsized IPO - Quiver Quantitative
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
New cancer radiopharma player Aktis Oncology raises $365M IPO - Stock Titan
RTW Biotech Opp.Aktis announces $318 million IPO - Research Tree
Inside Biotech: Eikon Therapeutics joins IPO queue with late-stage oncology focus - Proactive financial news
Major Insider Moves Signal Growing Confidence in Aktis Oncology - TipRanks
Aktis Oncology director Nodelman buys $40 million in shares - Investing.com
Aktis Oncology director Nodelman buys $40 million in shares By Investing.com - Investing.com India
There's a biotech boom in dealmaking - Axios
Eli Lilly-backed Aktis Oncology gets $317.7 million in US IPO - MSN
Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO - TipRanks
Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals - Dealbreaker
Aiming to become ‘generational leader’, Eikon goes public - The Pharma Letter
Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens - BioSpace
Aktis Oncology’s IPO tests reopening of biotech markets - The Pharma Letter
Inside Biotech: Aktis Oncology’s IPO signals early momentum for 2026 biotech markets - Proactive financial news
Biotech Market Awakens as Aktis Oncology Enters Public Arena - Kalkine Media
Aktis Oncology Prices Upsized IPO at $1 Billion Market Cap, Closes +24% - Intellectia AI
Aktis Oncology targets up to $945 million valuation in upsized US IPO - MSN
Aktis Oncology IPO Launches Amid $2 Billion Raised by Seven Biotech Follow-On Offerings - geneonline.com
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO - Seeking Alpha
Private biotechs draw $2B in huge fundraising week: Venture Report - BioCentury
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Bio IPO Delivers Breakout to Open 2026 Calendar - Smartkarma
Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors - Intellectia AI
Eikon looks to ride wave of IPO momentum - FirstWord
Aktis Oncology, Clinical-Stage Radiopharmaceutical Oncology, Files for Nasdaq Global Select Market IPO - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Eli Lilly-Backed Aktis Jumps 24% After $318 Million US IPO - Bloomberg.com
ICR Healthcare Kicks Off '26 IPO Year - O'Dwyer's PR
Aktis raises $318M in first biopharma IPO of 2026 - BioWorld MedTech
Aktis’ 25% IPO bounce builds hope for 2026’s public offerings - Endpoints News
Aktis Oncology Jumps 27% After $318 Million Upsized IPO - GuruFocus
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Business Wire
Lilly partner Aktis surges on trading debut (AKTS:NASDAQ) - Seeking Alpha
Aktis Oncology shares surge 50% in Nasdaq debut By Investing.com - Investing.com Nigeria
Aktis Oncology shares surge 50% in Nasdaq debut - Investing.com
Aktis Oncology soars in debut after upsized $318 million IPO - TradingView — Track All Markets
Boston-based Aktis, backed by Eli Lilly, jumps 24% after $318 million US IPO - The Boston Globe
Aktis breaks IPO ice with $318M Lilly-led offering - FirstWord
Aktis Oncology prices upsized US IPO at $18 per share - WSAU
Radiopharma-focused Aktis bring in $318M via upsized IPO - Fierce Biotech
Aktis Oncology prices IPO at $18 per share - MSN
Aktis Oncology Raises $318 Million at $18 per Share in IPO - Intellectia AI
Aktis raises $318M in 2026’s first biotech IPO - BioPharma Dive
4.73%
0.92%
자본화:
|
볼륨(24시간):